Biomimetic Nanocomposites Camouflaged with Hybrid Cell Membranes for Accurate Therapy of Early‐Stage Glioma

Glioma features high fatality rate and short survival time of patients due to its fast growth speed and high invasiveness, hence timely treatment of early‐stage glioma is extremely important. However, the blood brain barrier (BBB) severely prevents therapeutic agents from entering the brain; meanwhile, the non‐targeted distribution of agents always causes side effects to vulnerable cerebral tissues. Therefore, delivery systems that possess both BBB penetrability and precise glioma targeting ability are keenly desired. We herein proposed a hybrid cell membrane (HM) camouflage strategy to construct therapeutic nanocomposites, in which HM consisting of brain metastatic breast cancer cell membrane and glioma cell membrane was prepared with a simple membrane fusion pathway. By coating HM onto drug‐loaded nanoparticles, the as‐obtained biomimetic therapeutic agent (termed HMGINPs) inherited satisfying BBB penetrability and homologous glioma targeting ability simultaneously from the two source cells. HMGINPs exhibited good biocompatibility and superior therapeutic efficacy towards early‐stage glioma. Hybrid cell membranes (HMs) consisting of brain metastatic breast cancer cell membranes and glioma cell membranes were prepared and coated onto drug‐loaded nanoparticles. The obtained HMGINPs inherited good blood‐brain‐barrier penetration and homologous glioma targeting ability from the two types of source cells, and exhibited superior therapeutic efficacy against early‐stage glioma.